Risks and benefits of medications for panic disorder: a comparison of SSRIs and benzodiazepines
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Panic disorder (PD) is a prevalent and disabling anxiety disorder that can be treated effectively. Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines are among the most frequently prescribed drugs for PD. In this article, the authors review the current evidence on efficacy, adverse events, and limitations of these two treatment options. AREAS COVERED: MEDLINE/Pubmed and Web of Science databases were searched for open or placebo-controlled trials on SSRIs and/or benzodiazepines in PD treatment. EXPERT OPINION: The literature search yielded 4,957 articles related to the theme. Of these, 24 articles were included in this review. Despite their usefulness in PD, SSRIs are associated with a delay of several weeks in onset of therapeutic effect and have the potential to exacerbate anxiety and panic early in the treatment course. Benzodiazepines present rapid onset of action, but can cause tolerance and dependence. Despite strong evidence of the effectiveness of SSRIs and benzodiazepines in the treatment of PD, few trials have performed head-to-head comparisons of these two drug classes. Future studies on the pharmacological treatment of PD should make direct comparisons of risks, benefits, and limitations of each group. This could help improve the evidence-based pharmacotherapy of PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Figure 1) [8].”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The spectrum of behaviors influenced by serotonin
Lucki, I. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00139-5 · Cited by 1,158 · cited 1×
“areas with its neuronal cell bodies in the brainstem raphe nuclei and widespread axonal projections to the forebrain regions [3].”
BackgroundNeuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004 · cited 1×
“[2], panic attacks originate from a dysfunction in the brain’s fear network that integrates various structures of the brainstem, amygdala, medial hypothalamus, and cortical regions.”
BackgroundMechanism of action of serotonin selective reuptake inhibitors
Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540 · cited 7×
“Increased serotonin in these areas may be responsible for the insomnia and sleep disruption seen with SSRIs [52].”
BackgroundInfluentialAddiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Hooked on benzodiazepines: GABAA receptor subtypes and addiction
Tan, K. R., Rudolph, U., & Lüscher, C. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.01.004 · Cited by 365 · cited 15×
“GABAA are ligand-gated chloride-selective ion channels that are physiologically activated by GABA, the main inhibitory neurotransmitter in the brain.”
BackgroundInfluentialAndrade, C., Sandarsh, S., Chethan, K. B., & Nagesh, K. S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05786blu · Cited by 302 · cited 1×
“Abnormal bleeding [68] and hyponatremia [69] are also associated with SSRI use.”
BackgroundLiu, B. A., Mittmann, N., Knowles, S. R., & Shear, N. H. (1996) · Europe PMC (PubMed Central) · Cited by 290
Goddard, A. W., Mason, G. F., Almai, A., Rothman, D. L., Behar, K. L., Petroff, O. A. C., Charney, D. S., & Krystal, J. H. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.556 · Cited by 255 · cited 1×
“Singlephoton emission computed tomography studies have shown that patients with PD have decreased benzodiazepine receptor binding [5], and a magnetic resonance spectroscopy study revealed a significant overall reduction in total occipital GABA concentrations in patients with PD compared to normal controls [6], which s…”
Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
Ballenger, J. C., Wheadon, D. E., Steiner, M., Bushnell, W., & Gergel, I. P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.36 · Cited by 220
Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.
(2000) · PubMed Central · Cited by 207
ECT, Research, and Professional Ambivalence
Salzman, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.1 · Cited by 175
SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder
Bremner, J. D., Innis, R. B., White, T., Fujita, M., Silbersweig, D., Goddard, A. W., Staib, L., Stern, E., Cappiello, A., Woods, S., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00188-2 · Cited by 170 · cited 1×
“Singlephoton emission computed tomography studies have shown that patients with PD have decreased benzodiazepine receptor binding [5], and a magnetic resonance spectroscopy study revealed a significant overall reduction in total occipital GABA concentrations in patients with PD compared to normal controls [6], which s…”
Offidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Sertraline in the Treatment of Panic Disorder: A Flexible-Dose Multicenter Trial
Pollack, M. H., Otto, M. W., Worthington, J. J., Manfro, G. G., & Wolkow, R. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.1010 · Cited by 144 · cited 4×
“[17] Sertraline x placebo 50–200mg 10 weeks 176 NA Sertraline: 0.”
BackgroundInfluentialLondborg, P. D., Wolkow, R., Smith, W. T., Duboff, E., England, D., Ferguson, J., Rosenthal, M., & Weise, C. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.54 · Cited by 141 · cited 2×
“Dry mouth, dyspepsia, headache [10,14,15], tremor, asthenia, drowsiness, and insomnia [14,20] were also reported as side effects of SSRIs in PD.”
BackgroundStahl, S. M., Gergel, I., & Li, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1107 · Cited by 139 · cited 2×
“[23] compared escitalopram and citalopram versus placebo in 351 patients.”
BackgroundResultSertraline in the Treatment of Panic Disorder: A Double-Blind Multicenter Trial
Pohl, R. B., Wolkow, R. M., & Clary, C. M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1189 · Cited by 133 · cited 3×
“[16] Sertraline x placebo 25–200mg 10 weeks 166 0.”
BackgroundSerotonin Function in Panic Disorder: Important, But Why?
Maron, E., & Shlik, J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300880 · Cited by 129 · cited 1×
“gray-amygdala pathway, in order to inhibit hyperactivity or spontaneous neuronal discharge in this region [4].”
BackgroundBruce, S. E., Vasile, R. G., Goisman, R. M., Salzman, C., Spencer, M., Machan, J. T., & Keller, M. B. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1432 · Cited by 127 · cited 2×
“In the past decade, this class remained one of the most prescribed medications for the treatment of PD [24].”
BackgroundMichelson, D., Lydiard, R. B., Pollack, M. H., Tamura, R. N., Hoog, S. L., Tepner, R., Demitrack, M. A., Tollefson, G. D., & the Fluoxetine Panic Disorder Study Group (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1570 · Cited by 123 · cited 3×
“[12] Fluoxetine x placebo 10–20 mg 10 weeks 243 NA Fluoxetine: superior to placebo for panic frequency, phobia, disability, global improvement + Michelson et al.”
BackgroundMethodInfluentialEfficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder
Sheehan, D. V., Burnham, D. B., Iyengar, M. K., Perera, P., & Paxil CR Panic Disorder Study Group (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0105 · Cited by 85 · cited 1×
“[11] Paroxetine CR x placebo 25–75mg 10 weeks 889 1.”
BackgroundPanic disorder and social anxiety disorder subtypes in a caffeine challenge test
Nardi, A. E., Lopes, F. L., Freire, R. C. R., Veras, A. B., Nascimento, I., Valença, A. M., Neto, V. L. D. M., Soares‐Filho, G. L., King, A. L. S., Araújo, D. M. R., et al. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.023 · Cited by 81 · cited 2×
“A variety of trials induced acute panic attacks in PD patients under laboratory conditions [26].”
BackgroundMethodAsnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D. W., Jameel, M., Desagani, K., & Woods, S. W. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00265-7 · Cited by 79 · cited 4×
“These results were not corroborated by Asnis [20] in a 6- week study of 87 PD patients randomized to receive either fluvoxamine (100–300mg/day) or placebo.”
BackgroundResultInfluentialRosenbaum, J. F., Moroz, G., & Bowden, C. L. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00008 · Cited by 75 · cited 3×
“Rosenbaum [49] performed a 9week dose–response study (clonazepam dose escalated over 3 weeks to 0.”
BackgroundMethodFreire, R. C., Perna, G., & Nardi, A. E. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.493744 · Cited by 72 · cited 1×
“Some authors have postulated subtypes like the respiratory subtype (RS) and the non-RS [44,45].”
BackgroundMoroz, G., & Rosenbaum, J. F. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0907 · Cited by 68 · cited 4×
“Moroz and Rosenbaum [48] conducted a 6-week dose-optimization study (clonazepam 0.”
BackgroundInfluentialMichelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.514 · Cited by 62 · cited 3×
“[14] Fluoxetine x placebo 10–20mg 12 weeks 180 0.”
BackgroundAntidepressants and benzodiazepines for panic disorder in adults
Bighelli, I., Trespidi, C., Castellazzi, M., Cipriani, A., Furukawa, T. A., Girlanda, F., Guaiana, G., Koesters, M., & Barbui, C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011567.pub2 · Cited by 57 · cited 6×
“In studies evaluating benzodiazepines and SSRIs combination treatment, such as clonazepamsertraline or clonazepam-paroxetine [59], it was demonstrated that the combination treatment induced a more rapid response than the SSRI treatment alone [60].”
BackgroundInfluentialNardi, A. E., Freire, R. C., Mochcovitch, M. D., Amrein, R., Levitan, M. N., King, A. L., Valença, A. M., Veras, A. B., Paes, F., Sardinha, A., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823fe4bd · Cited by 56 · cited 3×
“Therefore, the coadministration of benzodiazepines in the first weeks of treatment may lower the ‘activation’ induced by the SSRI and reduce severity and frequency of panic attacks before the SSRI become effective [57].”
BackgroundInfluentialSelf-citationMichelson, D., Pollack, M., Lydiard, R. B., Tamura, R., Tepner, R., Tollefson, G., & The Fluoxetine Panic Disorder Study Group (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.3.213 · Cited by 54 · cited 2×
“to placebo with no tapering period [13].”
BackgroundClonazepam in the treatment of psychiatric disorders: an update
Nardi, A. E., & Perna, G. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194379.65460.a6 · Cited by 52 · cited 1×
“In comparison to patients with generalized anxiety, PD patients are more likely to be unsuccessful in discontinuing benzodiazepines [62].”
BackgroundNardi, A. E., Lopes, F. L., Valença, A. M., Nascimento, I., Mezzasalma, M. A., & Zin, W. A. (2004) · Psychopathology · doi:10.1159/000077017 · Cited by 48
PECKNOLD, J., LUTHE, L., MUNJACK, D., & ALEXANDER, P. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199410000-00005 · Cited by 46
Freire, R. C. R., Lopes, F. L., Valença, A. M., Nascimento, I., Veras, A. B., Mezzasalma, M. A., Neto, V. L. D. M., Zin, W. A., & Nardi, A. E. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.07.015 · Cited by 44 · cited 1×
“Some authors have postulated subtypes like the respiratory subtype (RS) and the non-RS [44,45].”
BackgroundNardi, A. E., Valença, A. M., Nascimento, I., Lopes, F. L., Mezzasalma, M. A., Freire, R. C. R., Veras, A. B., Zin, W. A., & Versiani, M. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2005.05.011 · Cited by 44 · cited 2×
“[47] described the therapeutic response of RS PD patients versus non-RS treated openly with clonazepam (1–4 mg/day) for 3 years.”
BackgroundDouble-blind acute clonazepam vs. placebo in carbon dioxide-induced panic attacks
Nardi, A. E., Valença, A. M., Nascimento, I., Mezzasalma, M. A., & Zin, W. A. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00135-9 · Cited by 44 · cited 3×
“Nardi et al. [47] described the therapeutic response of RS PD patients versus non-RS treated openly with clonazepam (1–4 mg/day) for 3 years.”
BackgroundInfluential(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1760 · Cited by 44 · cited 1×
“[63], 36 patients with PD and 35 patients with generalized anxiety disorder entered a controlled discontinuation phase after 2 months of alprazolam.”
BackgroundCaffeine challenge test in panic disorder and depression with panic attacks
Nardi, A. E., Lopes, F. L., Valença, A. M., Freire, R. C. R., Veras, A. B., Neto, V. L. D. M., Nascimento, I., King, A. L. S., Mezzasalma, M. A., Soares‐Filho, G. L., et al. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2006.12.001 · Cited by 43 · cited 1×
“These experiments used different methods, such as oral administration of caffeine [26,27], breath-holding [28–30], hyperventilation [29–36], and respiratory challenge tests with CO2 inhalation [37–40].”
MethodTapering Clonazepam in Patients With Panic Disorder After at Least 3 Years of Treatment
Nardi, A. E., Freire, R. C., Valença, A. M., Amrein, R., de Cerqueira, A. C. R., Lopes, F. L., Nascimento, I., Mezzasalma, M. A., Veras, A. B., Sardinha, A., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181dcb2f3 · Cited by 41 · cited 2×
“The main reported symptoms during clonazepam discontinuation were anxiety, irritability, nausea, vomiting, insomnia, nightmares, excessive sudoresis, tachycardia, headache, weakness, shaking, tremor, muscle aches, stiffness, hyperventilation, panic attacks, memory or concentration difficulties, muscle fasciculation, a…”
BackgroundMethoddo Amaral, J. M. X., Spadaro, P. T. M., Pereira, V. M., Silva, A. C. D. O. E., & Nardi, A. E. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-1045 · Cited by 40
Clonazepam for the Treatment of Panic Disorder
E. Nardi, A., Machado, S., Ferreira Almada, L., Paes, F., Cardoso Silva, A., Jose Marques, R., Amrein, R., C. Freire, R., Martin-Santos, R., Cosci, F., et al. (2013) · Current Drug Targets · doi:10.2174/1389450111314030007 · Cited by 40
Long-term effects of alprazolam on memory: a 3·5 year follow-up of agoraphobia/panic patients
KILIÇ, C., CURRAN, H. V., NOSHIRVANI, H., MARKS, I. M., & BA[Sogon];OĞLU, M. (1999) · Psychological Medicine · doi:10.1017/s003329179800734x · Cited by 39
Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine
Nardi, A. E., Valença, A. M., Freire, R. C., Mochcovitch, M. D., Amrein, R., Sardinha, A., Levitan, M. N., Nascimento, I., de-Melo-Neto, V. L., King, A. L., et al. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011000400015 · Cited by 39 · cited 1×
“The most common side effects reported in the clonazepam group were difficulties in memory and concentration [55,56].”
BackgroundDouble-blind clonazepam vs placebo in panic disorder treatment
VALENÇA, A. M., NARDI, A. E., NASCIMENTO, I., MEZZASALMA, M. A., LOPES, F. L., & ZIN, W. (2000) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2000000600008 · Cited by 38 · cited 1×
“[50] treated 24 PD patients with clonazepam 2 mg/day or placebo.”
MethodNew treatment options for panic disorder: clinical trials from 2000 to 2010
Freire, R. C., Hallak, J. E., Crippa, J. A., & Nardi, A. E. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.562200 · Cited by 37
Nardi, A. E., Valença, A. M., Mezzasalma, M. A., Lopes, F. L., Nascimento, I., Veras, A. B., Freire, R. C., de-Melo-Neto, V. L., & Zin, W. A. (2006) · Depression and Anxiety · doi:10.1002/da.20165 · Cited by 35
Hyperventilation challenge test in panic disorder and depression with panic attacks
Nardi, A. E., Valença, A. M., Nascimento, I., & Zin, W. A. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00335-3 · Cited by 32
Bertani, A., Caldirola, D., Bussi, R., Bellodi, L., & Perna, G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00003 · Cited by 32
Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine
Nardi, A. E., Valença, A. M., Freire, R. C. R., et al. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500020 · Cited by 28
Self-citationSandmann, J., Lörch, B., Bandelow, B., Härtter, S., Winter, P., Hiemke, C., & Benkert, O. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979311 · Cited by 27 · cited 2×
“[19] Fluvoxamine x placebo Average 160 mg 6 weeks 46 NA Fluvoxamine: 47.”
BackgroundResultNardi, A. E., Valença, A. M., Lopes, F. L., Nascimento, I., Mezzasalma, M. A., & Zin, W. A. (2004) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2004000200013 · Cited by 25
A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan
Kamijima, K., Kuboki, T., Kumano, H., Burt, T., Cohen, G., Arano, I., & Hamasaki, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000171518.25963.63 · Cited by 23 · cited 1×
“[18] evaluated the efficacy and safety of sertraline for 8 weeks in Japanese patients with PD.”
BackgroundParoxetine-induced increase in LDL cholesterol levels
Mellédo, J. L., Mailo, K., Lara, N., Abadia, M. D. P. C., Gil, L., Ameringen, M. V., Baker, G. B., & Perez-Parada, J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094320 · Cited by 23 · cited 1×
“cause increased lipid levels in PD patients [66,67].”
BackgroundPanic disorder and hyperventilation
NARD, A. E., Valença, A. M., Nascimento, I., Mezzasalma, M. A., & Zin, W. A. (1999) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1999000600006 · Cited by 23
Panic disorder in a breath-holding challenge test: a simple tool for a better diagnosis
Nardi, A. E., Nascimento, I., Valença, A. M., Lopes, F. L., Mezzasalma, M. A., & Zin, W. A. (2003) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2003000500003 · Cited by 22
Therapeutic response to benzodiazepine in panic disorder subtypes
Valença, A. M., Nardi, A. E., Mezzasalma, M. A., Nascimento, I., Zin, W. A., Lopes, F. L., & Versiani, M. (2003) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802003000200009 · Cited by 20 · cited 5×
“In a 6-week placebo-controlled trial, Valença et al. [50] treated 24 PD patients with clonazepam 2 mg/day or placebo.”
BackgroundResultInfluentialFreire, R. C., Amrein, R., Mochcovitch, M. D., Dias, G. P., Machado, S., Versiani, M., Arias-Carrión, O., Carta, M. G., & Nardi, A. E. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000740 · Cited by 20 · cited 1×
“pared to antidepressants, even if the effect was very small and close to no difference [60,61].”
BackgroundPanic disorder and obsessive compulsive disorder in a hyperventilation challenge test
Nardi, A. E., Valença, A. M., Nascimento, I., & Zin, W. A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00359-1 · Cited by 18
Hyperventilation in panic disorder patients and healthy first-degree relatives
Nardi, A. E., Valença, A. M., Nascimento, I., Mezzasalma, M. A., Lopes, F. L., & Zin, W. A. (2000) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2000001100009 · Cited by 18
Hyperventilation in Panic Disorder and Social Phobia
Nardi, A. E., Valença, A. M., Nascimento, I., Mezzasalma, M. A., & Zin, W. A. (2001) · Psychopathology · doi:10.1159/000049294 · Cited by 17
Choi, K.-W., Woo, J.-M., Kim, Y.-R., Lee, S.-H., Lee, S.-Y., Kim, E.-J., Chung, S.-K., Kang, E.-H., Lee, J.-H., & Yu, B.-H. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.1.44 · Cited by 17 · cited 2×
“[21] Escitalopram 5–20 mg 24 weeks 119 NA 73.”
BackgroundNardi, A. E., Valença, A. M., Mezzasalma, M. A., Levy, S. P., Lopes, F. L., Nascimento, I., Freire, R. C. R., Veras, A. B., & Zin, W. A. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.07.032 · Cited by 17
Carbon dioxide induced panic attacks and short term clonazepam treatment: preliminary study
NARDI, A. E., VALENÇA, A. M., ZIN, W., & NASCIMENTO, I. (1999) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1999000300003 · Cited by 16 · cited 1×
“These results corroborate a pilot study with PD patients in which CO2-induced attacks were attenuated after approximately 10 days of clonazepam 2 mg/day [43].”
ResultSome notes on a historical perspective of panic disorder
Nardi, A. E. (2006) · Jornal Brasileiro de Psiquiatria · doi:10.1590/s0047-20852006000200010 · Cited by 16 · cited 1×
“PD has been treated primarily with drugs that have anxiolytic properties, including benzodiazepines [7].”
BackgroundRandomized, Open Naturalistic, Acute Treatment of Panic Disorder With Clonazepam or Paroxetine
Nardi, A. E., Valença, A. M., Freire, R. C. R., Amrein, R., Sardinha, A., Levitan, M. N., Nascimento, I., Neto, V. L. D. M., King, A. L. S., Silva, A. C. D. O. E., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318210b4ee · Cited by 16 · cited 1×
“In studies evaluating benzodiazepines and SSRIs combination treatment, such as clonazepamsertraline or clonazepam-paroxetine [59], it was demonstrated that the combination treatment induced a more rapid response than the SSRI treatment alone [60].”
BackgroundCarbon dioxide test as an additional clinical measure of treatment response in panic disorder
Valença, A. M., Nardi, A. E., Nascimento, I., Zin, W. A., & Versiani, M. (2002) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2002000300003 · Cited by 13 · cited 2×
“In an open trial also involving CO2 challenge, 86% of PD patients who had a panic attack after CO2 challenge at baseline did not have a panic attack after CO2 challenge following 6 weeks of treatment with clonazepam 2 mg/day [37].”
BackgroundEarly carbon dioxide challenge test may predict clinical response in panic disorder
Valença, A. M., Nardi, A. E., Nascimento, I., Zin, W. A., Lopes, F. L., Mezzasalma, M. A., & Versiani, M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00222-6 · Cited by 13 · cited 2×
“These findings were confirmed in a double-blind study of 34 PD patients, where the panicogenic effect of CO2 was significantly attenuated after an acute dose of clonazepam (2 mg/day) and after 2 and 6 weeks of treatment, compared to placebo [41].”
BackgroundResultLopes, F. L., Oliveira, M. M., Freire, R. C. R., Caldirola, D., Perna, G., Bellodi, L., Valença, A. M., Nascimento, I., Piedade, R. A. M., Ribeiro, P. F. M., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903144012 · Cited by 13
Panic Disorder, Treatment With Selective Serotonin Reuptake Inhibitors, and Cholesterol Levels
Herrán, A., Ramírez, M. L., Carrera-Arce, M., García‐Unzueta, M. T., Sierra‐Biddle, D., Rodríguez‐Cabo, B., Ayestarán, A., Hoyuela, F., & Vázquez‐Barquero, J. L. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000237941.56107.b7 · Cited by 11 · cited 1×
“cause increased lipid levels in PD patients [66,67].”
Background
Research works printed but not linked: 6
- Association WGOPDAP, 1998, Am J Psychiatry, 155, 1
- Black K., 2000, J Psychiatry Neurosci, 25, 255
- Nardi AE, 2013, Curr Drug Targets, 14, 353
- Longo LP, 2000, Am Fam Physician, 61, 2121
- Bighelli I, 2016, Cochrane Lib
- Liu B.A., 1996, Can Med Assoc J, 155, 519
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“The subjects were interviewed with surgery-based consultations for approximately 10 min [12].”
BackgroundNasir, M., Trujillo, D., Levine, J. L. S., Dwyer, J. B., Rupp, Z. W., & Bloch, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.548505 · Cited by 107
“Long-term use of benzodiazepines can be associated with dependency (and thus reduced efficacy at a given dose), rebound anxiety, a discontinuation syndrome and memory impairment (15).”
BackgroundQuagliato, L. A., Cosci, F., Shader, R. I., Silberman, E. K., Starcevic, V., Balon, R., Dubovsky, S. L., Salzman, C., Krystal, J. H., Weintraub, S. J., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119859372 · Cited by 35
“In addition, the combination of SSRIs and BZs in the first weeks of PD treatment is recommended (Quagliato et al., 2018).”
BackgroundBeta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis
Archer, C., Wiles, N., Kessler, D. A., Turner, K. M., & Caldwell, D. M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.068 · Cited by 40
Shigetsura, Y., Imai, S., Endo, H., Shimizu, Y., Ueda, K., Murai, T., Itohara, K., Nakagawa, S., Yonezawa, A., Ikemi, Y., et al. (2022) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000499 · Cited by 31
Metadata
- Authors
- Quagliato, L. A., Freire, R. C., & Nardi, A. E.
- Affiliations
- Universidade Federal do Rio de Janeiro (BR)
- Laboratory of Panic & Respiration, Institute of Psychiatry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
- Corresponding author
- Quagliato, Laiana A.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2018-01-22
- Volume
- 17
- Issue
- 3
- Pages
- 315-324
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2794421769
- Cited by
- 62
- References
- 71
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 25 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 3
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- panic disorder, selective serotonin reuptake inhibitors, benzodiazepines, pharmacotherapy, drug efficacy, adverse drug reactions, benzodiazepine dependence, tolerance (pharmacology and immunology), head-to-head comparison
- MeSH terms
- Benzodiazepines, Drug Tolerance, Humans, Time Factors, Panic Disorder, Selective Serotonin Reuptake Inhibitors, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.